Clinical trials: Peripheral T-Cell Lymphoma Recurrent
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
RATIONALE: Giving high doses of chemotherapy drugs, such as busulfan and cyclophosphamide, before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT01177371
- Testing
- busulfan, cyclophosphamide, allogeneic bone marrow transplantation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
This randomized phase III trial studies how well graft-vs-host disease (GVHD) prophylaxis works in treating patients with hematologic malignancies undergoing unrelated donor peripheral blood stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01231412
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 174 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma, Small Intestine Cancer
Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug, giving the drugs in different ways, and combining biological therapy with…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00005021
- Testing
- filgrastim, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Fox Chase Cancer Center
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Giving vaccine therapy after an autologous stem cell transplant may kill any cancer cells that remain after transplant.
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer
- Trial name
- NCT00569309
- Testing
- Streptococcus pneumoniae, laboratory correlative studies, quality-of-life assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Anemia, Leukemia
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00255749
- Testing
- epoetin alfa
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
Phase I trial to study the effectiveness of irinotecan plus cyclosporine and phenobarbital in treating patients who have solid tumors or lymphoma that is refractory to standard therapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Neutropenia, Small Intestine Cancer
- Trial name
- NCT00002759
- Testing
- cyclosporine, irinotecan hydrochloride, phenobarbital
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
506U78 in Treating Patients With Lymphoma
Phase II trial to study the effectiveness of 506U78 in treating patients who have lymphoma that has not been treated previously or that has not responded to previous treatment.
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Trial name
- NCT00005080
- Testing
- nelarabine
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of genetically modified T-cells following peripheral blood stem cell transplant in treating patients with recurrent or high-risk non-Hodgkin lymphoma.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma
- Trial name
- NCT01815749
- Testing
- autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Lymphoma, Prostate Cancer
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as AMG-479, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00562380
- Testing
- ganitumab, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Amgen
Relapsed or Refractory Non-Hodgkin's Lymphoma
Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
This is an open-label, multicenter, phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in adult subjects with Relapsed/Refractory Non-Hodgkin Lymphomas.
- Trial name
- NCT05965505
- Testing
- AXT-1003
- Where
- 4 sites in China
- Volunteers
- 1 people
- Sponsor
- Axter Therapeutics (Beijing) Co., Ltd
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells.
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT01643603
- Testing
- Dasatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia, Lymphoma
Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003294
- Testing
- filgrastim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Chronic Myeloproliferative Disorders
Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients
RATIONALE: Understanding the emotional needs of spouses or others who are living with and caring for patients who have undergone stem cell transplantation may help improve the quality of life of both the caregivers and the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00082654
- Testing
- psychosocial assessment and care
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: A walking program may improve the ability to carry out daily activities after donor bone marrow transplant. PURPOSE: This randomized clinical trial is studying a structured walking program to see how well it works…
- Trial name
- NCT00445731
- Testing
- exercise intervention, management of therapy complications, observation
- Volunteers
- 115 people
- Sponsor
- University of Minnesota
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma
This phase I trial is studying the side effects and best dose of carmustine given together with O(6)-benzylguanine in treating patients with stage I or stage II cutaneous T-cell lymphoma that has not responded to previous…
- Conditions
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
- Trial name
- NCT00003613
- Testing
- O6-benzylguanine, carmustine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
This phase II trial studies the side effects and best dose of venetoclax and romidepsin to see how well it works in treating patients with mature T-cell lymphoma that has come back (recurrent) or does not respond to treatment…
- Conditions
- Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT03534180
- Testing
- Laboratory Biomarker Analysis, Romidepsin, Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Persistent or Recurrent Cutaneous T-Cell Lymphoma
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
The purpose of this trial is to assess the efficacy of E7777 in participants with recurrent or persistent Cutaneous T-Cell Lymphoma (CTCL) in Stage I - III participants as assessed by objective response rate (ORR).
- Trial name
- NCT01871727
- Testing
- E7777 9 mcg/kg
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 112 people
- Sponsor
- Eisai Inc.
Leukemia, Lymphoma
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and cyclophosphamide, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00782379
- Testing
- busulfan, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northside Hospital, Inc.
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Penclomedine in Treating Patients With Solid Tumors or Lymphoma
Phase I trial to study the effectiveness of penclomedine in treating patients with malignant solid tumors or lymphomas. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002946
- Testing
- penclomedine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolumab, and cemiplimab in treating patients with multiple myeloma, acute…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome
- Trial name
- NCT03017820
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Mayo Clinic